Moleculin BiotechMBRX

13F holders, Q2 2026 (June 30)
18holders −2
5new positions
7sold out
$2.79avg. 13F price*

At the end of Q2 2026, 18 institutions reported holding Moleculin Biotech Inc. (MBRX) in their 13F filings, down 2 from Q1 2026. 5 opened new positions and 7 sold out. The largest holders were Geode Capital Management, LLC ($132K), Vanguard Capital Management LLC ($118K) and Vanguard Fiduciary Trust Co. ($83K).

Company
Moleculin Biotech Inc.
CUSIP
60855D408
Latest filing quarter
Q2 2026

History

Number of 13F holders

05101520 Q4 2025: 17Q4 2025Q1 2026: 20Q1 2026Q2 2026: 18Q2 2026

Total Exit/New Position Q1 2026 → Q2 2026

InstitutionsTotal Value
New Positions5$75K
Exits7$211K

All 13F filers, Q1 2026 → Q2 2026: 126,136 shares bought and 92,479 shares sold, net +33,657 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.

Ownership 18 holders

Geode Capital Management, LLC 0.00% Add +46.2% 47,252 $132K
Vanguard Capital Management LLC 0.00% Add +204.4% 42,215 $118K
Vanguard Fiduciary Trust Co. 0.00% Add +392.1% 29,883 $83K
XTX Topco Ltd 0.00% New 22,942 $64K
Morgan Stanley 0.00% Add +55555.6% 20,036 $56K
Rockefeller Capital Management L.P. 0.00% Add +239.3% 15,000 $42K
Tower Research Capital LLC (TRC) 0.00% Add +91.5% 3,514 $10K
Citigroup Inc. 0.00% New 2,674 $7K
Barclays PLC 0.00% New 621 $2K
BlackRock, Inc. 0.00% No change 491 $1K
EFG International AG 0.00% No change 434 $1K
Jones Financial Companies LLLP 0.00% New 360 $1K
Wells Fargo & Company 0.00% New 200 $558
NFSG Corp 0.00% No change 114 $318
SBI Securities Co., Ltd. 0.00% Add +2.3% 44 $123
Danske Bank A/S 0.00% No change 2 $6
CVA Family Office, LLC 0.00% No change 1 $3
Osaic Holdings, Inc. 0.00% No change 1 $2

"% of holder's portfolio" is MBRX's weight in each manager's 13F, not the share of Moleculin Biotech Inc. the manager owns.